Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Gynecol Oncol. 2017 Oct 14;147(3):695–704. doi: 10.1016/j.ygyno.2017.10.003

Table 1.

Adverse Effects of PARP inhibitors

Olaparib
SOLO2/ENGOT-
Ov21 (n=195)		 Niraparib
NOVA/ENGOT-
OV16 (n=367)		 Rucaparib
ARIEL2 (n=204) /
ARIEL3 (n=374)		 Veliparib
Coleman, RL 2015
(n=50)		 Talazoparib
NCT01286987
(n=71)
Grade 3 and 4 adverse events

  • Anemia 38 (18%)

  • Fatigue 8 (4%)

  • Neutropenia 8 (4%)

  • Abdominal pain 5 (3%)

  • Nausea 5 (3%)

  • Vomiting 5 (3%)

  • Thrombocytopenia 2 (1%)

  • Thrombocytopenia 128 (33.8%)

  • Anemia 93 (25.3%)

  • Neutropenia 72 (19.6%)

  • Hypertension 30 (8.2%)

  • Fatigue 30 (8.2%)

  • Nausea 11 (3.0%)

  • Abdominal pain 4 (1.1%)

  • Anemia 22 (45%) / 70 (19%)

  • Fatigue 18 (9%) / 25 (7%)

  • Neutropenia 16 (7%) / 25 (7%)

  • Nausea 9 (4%) / 14 (4%)

  • Elevated AST/ALT 25 (13%) / 39 (10%)

  • Abdominal pain 5 (2%) / 9 (2%)

  • Thrombocytopenia 5 (2%) / 19 (5%)

  • Leukopenia 1 (2%)

  • Thrombocytopenia 1 (2%)

  • Neutropenia 1 (2%)

  • Nausea 2 (4%)

  • Metabolism/Nutrition 1 (2%)

  • Other Investigations 6 (12%)

  • Anemia 16 (23%)

  • Thrombocytopenia 13 (18%)

  • Neutropenia 7 (10%)

  • Fatigue 2 (3%)
Serious adverse events Total 35 (18%)

  • Anemia 7 (4%)

  • Abdominal pain 3 (2%)

  • Intestinal obstruction 3 (2%)

 Total 110 (30%)
  • ARIEL2: Total 50 (25%)
    • Intestinal obstruction 10 (5%)
    • Anemia 9 (4%)
  • ARIEL3: Total 78 (21%)
    • Anemia 16 (4%)
    • Pyrexia 6 (2%)
    • Vomiting 6 (2%)
    • Intestinal obstruction 3 (1%)
 Total 12 (24%) Not reported.
Changes in dose due to AE

  • Dose reductions 49 (25%)

  • Discontinuations 21 (11%)

  • Dose reductions: 244 (66.5%)

  • Discontinuations: 54 (14.7%)
  • ARIEL2:
    • Dose reductions: 80 (39%)
    • Discontinuations: 19 (9%)
  • ARIEL3:
    • Dose reductions: 203 (55%)
    • Discontinuations: 50 (13%)

  • Dose Reductions: 31 (62%)

  • Discontinuations: 31 (62%)*

 Dose reductions from 1.0mg/day dose: 26 (34%)
*

Dose reductions were offered to patients with significant adverse effects.